索拉非尼对门静脉高压症的治疗作用及其机制  

Therapeutic effect of sorafenib on portal hypertension: research progress and mechanisms

作　　者：朱云[1] 程旸[2] 李爱民[1] 罗荣城[1] 

机构地区：[1]南方医科大学中西医结合肿瘤中心,广东广州510315 [2]南方医科大学南方医院消化科,广东广州510515

出　　处：《南方医科大学学报》2014年第1期133-136,共4页Journal of Southern Medical University

基　　金：国家卫生部"十二五"课题(W2011BX043)

摘　　要：门静脉高压症是一组以门静脉压力升高、门体侧枝循环形成为特征的临床综合症,是肝硬化最主要的并发症之一。目前尚无治疗门静脉高压的理想药物,故有必要寻找可有效降低门静脉高压的药物。索拉非尼是口服的酪氨酸激酶抑制剂,已有研究表明,索拉非尼用于门静脉高压症可显著改善血流动力学、抑制新生血管形成、减轻肝脏的纤维化,明显降低门静脉压力。本文就索拉非尼治疗门静脉高压症的研究进展及其相应机制做一综述。Portal hypertension, as one of the major complications of liver cirrhosis, is a common clinical syndrome characterized by an increased portal pressure and the formation of portal-systemic collaterals. Currently no ideal therapeutic agent has been available for portal hypertension. Sorafenib is an oral tyrosine kinase inhibitor that has been shown to significantly improve blood flow dynamics, inhibit angiogenesis, reduce liver fibrosis and decrease portal pressure in the treatment of portal hypertension. The authors review the progress in the research of sorafenib in the treatment of portal hypertesion and the mechanisms of its actions.

关 键 词：门静脉高压 索拉非尼 血流动力学 肝星状细胞 新生血管形成 

分 类 号：R575.2[医药卫生—消化系统]